June 13, 2012 — Positron Corp. announced completion of its first strontium validation effort in May 2012, when Manhattan Isotope Technology (MIT), a Positron subsidiary, successfully processed strontium.


As the nation’s leading provider of maternal-fetal, newborn and pediatric subspecialty physician services, Pediatrix Medical Group says streamlining the transfer of images and reports is a priority. Seeking a faster, more reliable method of exchanging files than on CD, the group adopted a cloud-based medical information exchange. 

 

 

Best Cyclotron Systems is unveiling five new cyclotrons for isotope research and production at the Society of Nuclear Medicine (SNM) 2012 Annual Meeting on June 9-12 in Miami Beach, Fla.

Boston Scientific Corporation has closed its acquisition of Cameron Health and, as a result, added to its product portfolio the world's first and only commercially available subcutaneous implantable cardioverter defibrillator, called the S-ICD System. 

June 11, 2012 — Boehringer Ingelheim Pharmaceuticals Inc. announced that the Pradaxa (dabigatran etexilate mesylate) capsules prescribing information has been updated to affirm that "Pradaxa 150 mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin."

June 8, 2012 — Bayer HealthCare announced the formation of a strategic partnership with Radimetrics Inc. that will offer U.S. healthcare professionals the industry’s first computed tomography (CT) dose management software portfolio to include radiation and contrast dose tracking. Through the agreement, Bayer will distribute the Radimetrics eXposure Radiation Dose Management (RDM) software in addition to Bayer’s existing contrast-focused dose management solution.

June 11, 2012 — Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, and Health Diagnostic Laboratory Inc. (HDL) announced an agreement under which HDL will soon offer ST2 testing services based on Critical Diagnostics' Presage ST2 Assay.

June 11, 2012 — Calgary Scientific Inc. has received clearance from the U.S. Food and Drug Administration (FDA) to market its ResolutionMD Web 2.9 Vessel Analysis module for post-processing diagnostic review and analysis of patient computed tomography (CT) and magnetic resonance imaging (MRI) scans.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now